Amgen stock
Price history
+38.59% over the period1 year: from $336.00 (November 13, 2025) to $465.67 (November 13, 2026), +38.59%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 13, 2026 | $465.67 |
| October 30, 2026 | $466.01 |
| September 30, 2026 | $421.51 |
| August 31, 2026 | $429.88 |
| July 31, 2026 | $385.16 |
| June 30, 2026 | $362.12 |
| May 29, 2026 | $336.79 |
| April 30, 2026 | $346.25 |
| March 31, 2026 | $351.85 |
| February 27, 2026 | $388.16 |
| January 30, 2026 | $341.88 |
| December 31, 2025 | $327.31 |
| November 28, 2025 | $345.46 |
| November 13, 2025 | $336.00 |
At a glance
The company
Discovers, develops, manufactures, and delivers human therapeutics for rheumatoid arthritis, oncology, cardiovascular, bone health, and other diseases
Latest results
Quarter to September 30, 2026 · EPS $6.45 (estimate $5.76)
Next event
Dividend
TickerLandia's take on Amgen
- Pricier than usual relative to earnings: P/E on the latest fiscal year 33 vs a median of 22 over its last 10 fiscal years.
- Cheaper than similar companies: trailing 12-month P/E 27 vs 42 (−36%) in a group of 10.
- Strong point: Market momentum (86/100 in its group). Weak point: Financial strength (21/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−3.79% from the 52-week high
Analysts · 34 analysts
Average target$431.81−7.27% vs. price
Buy 11 · Hold 18 · Sell 5 · Hold
TickerLandia Fingerprint: Amgen
Compared with similar companies: very strong momentum.
Financials and price compared with 25 companies in the drug manufacturers - general industry, worldwide. Momentum and risk compared with 883 North American stocks.
Pricehigh79
How much it costs relative to what it produces.
Metric Value Position in group Forward P/E 18.6 73 P/E (trailing 12 months) 27.0 67 EV/EBITDA 16.6 86 Price/book 17.5 94 Price/sales 6.47 74 Profitabilityhigh66
How much it earns on revenue and capital.
Metric Value Position in group Net margin 24.1% 82 ROE 78.4% 94 ROA 8.9% 42 Gross margin 72.5% 42 Operating margin 34.1% 70 Earnings stabilityaverage40
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 5.5% 26 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 54 Growthhigh60
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) +11.77% 70 Earnings growth (year over year) +19.40% 60 Revenue growth (year over year) +8.50% 50 Financial strengthlow21
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Net debt/EBITDAcounts in reverse: lower means more financial strength 2.79 10 Interest coverage 3.66 10 Debt/equitycounts in reverse: lower means more financial strength 3.76 2 Current ratio 1.48 62 Dividendlow40
How much it returns to shareholders, and for how long.
Metric Value Position in group Consecutive dividend years 16 years 28 Dividend yield 2.2% 44 Payout ratio 57.6% 48 Market momentumvery strong86
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) +14.94% 84 Relative strength (6 months) +36.26% 90 Distance from 200-day average +22.22% 90 1-year return +38.59% 80 Risklow35
How much the price swings.
Metric Value Position in group Volatility (60 days) 33.8% 49 Beta (1 year) 0.51 41 Maximum drawdown (12 months) 16.6% 14
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Amgen is pricier than in the past and cheaper than similar companies
On the latest fiscal year's earnings (2025), Amgen's P/E today is 32.7, above the median of its last 10 fiscal years (21.8; between 14.3 and 64.6 from 2016 to 2025). Amgen's P/E (trailing 12 months): 27.0, −36% against the median of a group of 10 similar companies (42.3).
Compared with 10 similar companies
| Metric | Amgen | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 27.0 | Low | |
| Forward P/E | 18.6 | High | |
| Operating margin | 34.1% | Middle | |
| ROE | 78.4% | High | |
| Debt/equity | 3.76 | High |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Amgen. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$10.37B
Latest quarter · Q3 2026
Net income
$3.86B
Latest quarter · Q3 2026
Quarterly net margin
37.3%
Latest quarter · Q3 2026
Numbers and valuation
Full valuation- Market cap
- $251.89B
- P/E
- 27.0
- EPS
- $17.25
- Volume
- 2.12M
- Daily trading
- €1.12B
- Dividend yield
- 2.13%
How Amgen is changing
All resultsRevenue grew 7.6% a year on average over the last 5 years
Operating margin fell from 36.3% to 24.7%
Profits turn into cash: free cash flow equal to 140% of net income
Returns
Amgen returns with dividends
$1,000 invested in Amgen 5 years ago, on November 15, 2021, would be worth $2,601 today with dividends reinvested: +160.15% in total, +21.10% per year. On price alone it would be $2,245 (+124.53%).
| Period | Amgen | S&P 500 | $1,000 becomes |
|---|---|---|---|
| 1 month | +12.80% | −3.12% | $1,128 |
| 6 months | +38.41% | +1.58% | $1,384 |
| Year to date | +42.27% | +10.46% | $1,423 |
| 1 year | +42.42% | +12.23% | $1,424 |
| 3 years | +91.04% | +71.41% | $1,910 |
| 5 years | +160.15% | +61.48% | $2,601 |
| 10 years | +325.41% | +249.40% | $4,254 |
Over the last 6 months it has done better than 76% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. S&P 500: price only. Calculate your investment
The chart in detail
Amgen: technical analysis
Amgen is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 2.7% below its highest close since January 2, 1990 ($478.48, November 4, 2026).
- Trend
- Upward
- RSI (14 sessions)
- 62
- Between 30 and 70
- vs 200-session average
- +22.22%
Support and resistance
Price areas where Amgen has stopped several times in the last year. They describe the chart; they are not forecasts.
- No resistance above: the price is near the highs of the year
- Last price$465.67
- Support$446.63−4.09%3 touches, last on November 6, 2026
- Support$395.10−15.15%3 touches, last on October 6, 2026
- Support$376.62−19.12%3 touches, last on September 16, 2026
Volatility and risk
Over the last year it has moved less than the S&P 500.
- Beta (1 year) vs S&P 500
- 0.51
- Volatility (60 sessions, annualised)
- 33.8%
- Largest fall in the last year
- −16.57%
Close of November 13, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Amgen: seasonality
Average monthly price change over 37 years
Over the last 37 years, the strongest month for Amgen has been July: +8.03% on average, positive in 32 years out of 37. The weakest has been April: −0.47% on average, positive in 15 years out of 37. November, the current month, has been positive in 24 years out of 36 (+2.90% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +1.81% | +2.14% | 22 of 36 |
| February | +0.02% | −0.29% | 18 of 37 |
| March | +1.09% | +1.13% | 19 of 37 |
| April | −0.47% | −1.08% | 15 of 37 |
| May | +1.30% | −0.16% | 18 of 37 |
| June | +0.52% | +0.62% | 19 of 37 |
| July | +8.03% | +6.36% | 32 of 37 |
| August | +1.08% | +1.28% | 23 of 37 |
| September | +0.23% | −0.79% | 17 of 37 |
| October | +1.66% | +2.72% | 21 of 37 |
| November | +2.90% | +2.21% | 24 of 36 |
| December | +3.41% | +1.28% | 22 of 36 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Amgen and its competitors
Amgen's largest business is human therapeutics, which it discovers, develops, manufactures and delivers worldwide. Its principal products cover inflammatory diseases such as rheumatoid arthritis and psoriasis, bone disorders including osteoporosis, cardiovascular risk reduction, and cancers such as multiple myeloma and colorectal cancer, with brands including Enbrel, Otezla, Prolia, Repatha and KYPROLIS.
- Headquarters
- Thousand Oaks, United States
- Employees
- 31,500
- Founded
- 1980
- Chief executive
- Robert Bradway
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| AmgenAMGN | $251.89B | 34.1% | 27.0 | +38.41% |
| Gilead SciencesGILD | $208.48B | 38.2% | — | +26.33% |
| MerckMRK | $364.26B | 35.2% | 147.8 | +30.24% |
| PfizerPFE | $164.67B | 29.1% | 41.3 | +11.29% |
| Bristol-Myers SquibbBMY | $129.66B | 32.4% | 14.1 | +12.48% |
| AbbVieABBV | $521.5B | 36.6% | 50.6 | +41.50% |
Same industry or related industries, similar size. Compare Amgen with its competitors · Full profile
